To carry out a systematic review to evaluate the clinical and cost effectiveness of different methods of monitoring blood glucose control in diabetes mellitus. The citations in retrieved papers were also examined. Non-English language papers were included as too few articles were retrieved by searches restricted to English language publications only.
Assessment of study quality
The quality of the primary studies was assessed using a checklist for randomised and non-randomised studies (see Other Publications of Related Interest no.1). The checklist had been modified by adding an additional item concerning the range of outcome measures, and removing the item on power. The modified checklist had 27 items grouped by subscales for reporting external validity and internal validity. The overall quality score ranged from zero (lowest quality) to a maximum of 28 points. The statistical power of each study was assessed separately based on the estimated detectable per cent difference in the mean glycated haemoglobin between the groups. This was scored from 1 (3.00% or less) to 5 (0.25% or less). The quality of the studies was assessed independently by two reviewers using a checklist. Inter-rater reliability was calculated as the mean difference in the score for each subscale of the checklist. The final grading of each item was reached by discussion.
Data extraction
The authors do not state how the data were extracted for the review, or how many of the reviewers performed the data extraction. The following data were extracted from each included study and tabulated in the report: study setting, study design, the number of participants, the characteristics of the participants, intervention groups compared in the study, study duration, outcome measures, drop-outs, and results.
Methods of synthesis
How were the studies combined? The data were synthesised using a random-effects meta-analysis where possible, or in a narrative summary. Comparisons were made between the effect of any monitoring (blood or glucose) versus no monitoring, and blood monitoring versus urine monitoring, with respect to changes in glycated haemoglobin and weight. Publication bias was explored using funnel plots and associated tests (see Other Publications of Related Interest no.2).
How were differences between studies investigated?
The meta-analyses included a statistical test of heterogeneity. Where a meta-analysis was not possible or was inappropriate, the findings were summarised with a narrative description of the differences between the studies. These included differences in the setting and participants' characteristics, the testing methods and equipment used, the use of treatment protocols, reliability of monitoring, compliance, and confounding interventions.
Results of the review
Eight RCTs, including 734 patients, were included in the evaluation of the effectiveness of self-monitoring in Type 2 diabetes mellitus.
Eight controlled trials were included in the evaluation of the effectiveness of self-monitoring in Type 1 diabetes mellitus: 1 was an RCT (n=39), 1 was an RCT with factorial design (n=37), 3 were randomised crossover trials (n=82), 1 was a crossover trial that did not report the method of allocation (n=16), 1 used a sequential cluster allocation (n=86), and one was a non-randomised controlled trial (n=181).
Five RCTs were included in the evaluation of the effectiveness of self-monitoring of blood and urine glucose in women with GDM or diabetic pregnancy: 4 trials (n=158) were in women with diabetic pregnancy, and only one RCT (n=66) included women with GDM.
The number of studies included in the assessment of near-patient and laboratory testing was not explicit.
Self-monitoring in Type 2 diabetes mellitus.
The mean quality score for the 8 included RCTs was 15.0 (standard deviation 1.7), indicating poor conduct and reporting. All of the trials included too few patients to detect a difference of 0.5% or less in glycated haemoglobin, indicating low statistical power. The interventions were not standardised and the duration of the studies ranged between 4 and 12 months. Compared with no monitoring, there was no evidence that self-monitoring of blood or urine glucose improves blood glucose control, measured using glycated haemoglobin or fasting plasma glucose; the pooled difference in glycated haemoglobin was -0.25 ( 95% confidence interval, CI: -0.61, 0.10), based on 4 RCTs (n=285). There was no evidence that blood glucose monitoring was more effective than urine glucose monitoring in improving blood glucose control; the pooled difference in glycated haemoglobin was -0.03 (95% CI: -0.52, 0.47), based on 3 RCTs (n=278). The patients' perception of monitoring was not assessed adequately in the included studies. Urine testing was preferred by approximately 70% of patients in 2 RCTs.
Self-monitoring in Type 1 diabetes mellitus.
The mean quality score for the 8 included controlled trials was 14.4 (standard deviation 1.6), indicating poor conduct and reporting. Only one study had sufficient power to detect a difference in glycated haemoglobin of less than 1%, indicating low statistical power. It was difficult to combine the findings of the studies because of differences in design, participant selection, and the testing modalities compared. The combined treatment effect on glycated haemoglobin from self-monitoring of blood glucose, compared with self-monitoring of urine glucose, was -0.57 ( 95% CI: -1.07, -0.06), based on 5 studies (n=180, including 18 patients in a crossover study). The statistical significance was sensitive to assumptions regarding the correlation of initial and final measurements. The majority of patients in 6 studies seemed to prefer blood monitoring to urine testing.
GDM and diabetes in pregnancy.
The mean quality score for the 5 RCTs was 12.8 (standard deviation 3.5), indicating poor conduct and reporting. None of the trials had sufficient power to detect differences in less common maternal and foetal outcomes. A meta-analysis was not possible as the trials used different interventions and measured different outcomes. A narrative summary of the findings from the 5 RCTs concluded that women with Type 1 diabetes mellitus managed at home with SMBG, can achieve blood glucose control as good as that achieved by patients who receive intensive control in hospital. Hospital admission was less for women managed at home with SMBG. Maternal and foetal outcomes may be as good with SMBG at home, and this approach was preferred by the patients. In GDM, the monitoring of blood glucose after meals, rather than before, may lead to better metabolic control and foetal outcomes.
Near-patient and laboratory testing.
Indirect evidence from 2 RCTs suggested that the monitoring of glycated haemoglobin in Type 1 and Type 2 diabetes mellitus will be clinically effective. There was no evidence on the effectiveness of different testing frequencies.
Cost information
Yes. In Type 2 diabetes mellitus, urine testing was less costly than blood testing. In Type 1 diabetes mellitus, one study showed that blood testing was more costly than urine testing. With regard to near-patient and laboratory testing, indirect evidence from 2 RCTs suggested that the monitoring of glycated haemoglobin in Type 1 and Type 2 diabetes mellitus will be cost-effective.
